LOUISVILLE – The wait continues for the initial public offering of Louisville-based biopharmaceutical company GlobeImmune Inc. as Friday’s trading came and went without any trading activity.
The Nasdaq exchange’s website earlier this week had shown an expected date of Friday, June 27, for GlobeImmune’s IPO. A Nasdaq official said the company does not comment on prospective IPOs.
Officials for neither GlobeImmune nor Aegis Capital Corp., the lone book runner for the IPO, could be reached for comment Friday.
GlobeImmune filed for the IPO in March, later reducing the number of shares offered from 2.2 million to close to 1.6 million. The pricing is expected to be in the $15 to $17 per share range.
The company had previously filed for an IPO in 2012 before withdrawing it last year.